Overview

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease

Status:
Unknown status

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is find out how safe a single dose of bryostatin 1 is in patients with Alzheimer's Disease (AD). This study is also being done 1) to determine how effective a single dose of bryostatin 1 is in the treatment of AD, 2) to find out what happens to bryostatin 1 once it enters the body by measuring the levels of bryostatin 1 in blood, and 3) to measure a substance in the blood (protein kinase C) that may help to better understand how bryostatin 1 works.

Phase:

Phase 2

Details

Lead Sponsor:

Blanchette Rockefeller Neurosciences Insitute

Treatments:

Bryostatin 1